To evaluate the role of CCR2 in allergic asthma, mutant mice deficient in CCR2 (CCR2 ؊/؊ ) and intact mice were sensitized with i.p. OVA with alum on days 0 and 7, and challenged by inhalation with nebulization of either OVA or saline. Airway hyperreactivity, measured by the methacholine-provoked increase in enhanced pause, was significantly increased (p < 0.05) in OVAchallenged CCR2
A llergic asthma is believed to be a Th2-type immunological process (1) mediated by the cytokines IL-4 and IL-5 (2) . IL-4 stimulates B lymphocyte production of Agspecific IgE, which binds to Fc receptors on the surface of mast cells. When allergen makes contact with Ag-specific membranebound IgE on mast cells in the lung, the cells are triggered to release leukotrienes and cytokines, which induce airway hyperreactivity (AHR) 3 and inflammation. IL-4 also can promote airway inflammation by driving differentiation of CD4 ϩ T cells into Th2 cytokine-producing cells, including IL-5 (3). The release of IL-5 induces differentiation of eosinophils and eosinophil release from the bone marrow. Eosinophils are capable of inducing inflammation and increasing airway hyperreactivity through production of major basic protein, eosinophil peroxidase, eosinophil cationic protein, leukotrienes, superoxide, proinflammatory cytokines, and chemokines (4) . Major basic protein induces smooth muscle hyperreactivity, dysfunction of muscarinic M2 receptors, and degranulation of mast cells and basophils, all of which contribute to airway hyperreactivity and inflammation. A central role for IL-4 and IL-5 in human allergic asthma is supported by findings that patients with this disease have increased levels of these cytokines in bronchoalveolar lavage (BAL) fluid (5, 6) , and increased levels of IL-5 mRNA in bronchial mucosa (7) . The dependence of the allergic airway phenotype in mice on IL-4 and IL-5 signaling through their respective receptors has been demonstrated by using mice deficient in IL-4, IL-5, or STAT-6, an intracellular intermediate in the IL-4 signaling pathway (8 -11) or by blocking the binding of IL-4 or IL-5 to their receptors in vivo (12, 13) . These studies implicate an important role for these Th2 cytokines in the pathogenesis of allergic asthma.
There is increasing evidence that proinflammatory chemokines and their receptors also have a profound effect on pulmonary allergic responses (14, 15) . Among the chemokines detected in airways of patients with allergic asthma is monocyte chemotactic protein (MCP)-1 (16) . Various roles have been attributed to MCP-1 in promoting allergic responses, including recruitment of basophils (17) and clumping of mast cells (18) , IgE-independent induction of basophil (17) and mast cell (18) histamine release, chemotaxis of T cells (19) , and enhancement of polarization of naive T cells to IL-4-producing Th2 cells (20, 21) . Further evidence that MCP-1 may play a role in allergic asthma can be found in studies that observe that MCP-1 immunoneutralization resulted in reduction in AHR, pulmonary inflammation, and production of lymphocyte-derived inflammatory mediators in allergen-challenged animals (22) (23) (24) . Because CCR2 is the major receptor for MCP-1, it may also play a role in allergic bronchial hyperreactivity and inflammation.
Mice deficient in CCR2 exhibit a strong Th1 to Th2 switch in their immune responses to infectious challenge, as characterized by large increases in production of IL-4, IL-5, and anti-pathogenspecific Abs, including IgE (25, 26) . Considering this bias toward Th2 immunity in CCR2-deficient mice, we wanted to determine how these animals would respond in a noninfectious, Ag-driven model of allergic asthma. Consistent with the results from the infection models, CCR2-deficient mice sensitized to OVA and then rechallenged with aerosolized Ag showed a strong pulmonary Th2 response relative to the response of wild-type (wt) mice. The response included high levels of IL-5, Ag-specific Ig, and MCP-1, as well as profound bronchial eosinophilia, increased AHR, and Goblet cell hyperplasia. Taken together, these results provide evidence for an important role for CCR2 signaling pathways in Th2 immune responses. Defects in these pathways contribute to an enhanced Th2 phenotype, which in this case leads to the exacerbation of clinical features in this model of pulmonary allergy.
Materials and Methods

Animals
The experimental CCR2-deficient mice CCR2
Ϫ/Ϫ on a mixed 129/Ola and C57BL/6 background (27) and wt mice on a mixed 129 ϫ C57BL/6 background were bred in the Animal Resource Facility at the University of Virginia (Charlottesville, VA). Inbred C57BL/6 and 129/SvJ mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). All animal procedures were approved by the Animal Research Committee at the University of Virginia, and all procedures conform to the Guide for the Care and Use of Laboratory Animals by the Institute of Laboratory Animal Resources. For lung BAL and fixation of lung tissue, deep anesthesia was induced by i.p. injection of ketamine (80 mg/kg) and xylazine (8 mg/kg) followed by euthanasia by exsanguination.
OVA sensitization and challenge
On days 0 and 7, mice received an i.p. injection of 25 g of chicken egg OVA (Sigma, St. Louis, MO) mixed with 2 mg of alum (Pierce, Rockford, IL) in 100 l of 0.9% NaCl (normal saline). Beginning 14 days after this initial sensitization, animals were challenged every other day for 16 days (8 treatments in total) with either inhalation of 1% OVA in normal saline or inhalation of normal saline alone. For each 20-min challenge, animals were placed in a 1.3-liter plastic chamber connected to the aerosol output from a Ultra-Neb99 nebulizer (DeVilbiss, Somerset, PA).
Measurement of AHR
AHR was measured as we have described previously (28) by using the enhanced expiratory pause (Penh) in plethysmographic box pressure during expiration (Buxco Electronics, Sharon, CT). Free-moving conscious mice were evaluated in closed plethysmographic chambers through which continuous airflow refreshed the air supply. Penh was calculated by computer analysis of plethysmographic (box) pressure curves generated by each inhalation (negative pressure) and exhalation (positive pressure wave) with BioSystem XA software, version 1.5 (Buxco Electronics, Sharon, CT). Expiratory pressure was measured against time. Total exhalation time (Te) was the time from initiation of exhalation until the box pressure became zero. With an arbitrarily defined percentage of 65%, the computer divided the expiratory pressure-time curve into an area 65% of which represented the time from onset of expiration to the time-point representing 65% of the area. The time under this area was the relaxation time (Tr). The subsequent 35% of area of the pressure-time curve at the latter part of expiration was the pause time (Tp), such that Te ϭ Tr ϩ Tr. Penh was calculated by the computer by multiplying the ratio of Tp/Tr by the ratio of peak expiratory box pressure (PEP) to peak inspiratory box pressure (PIP) by the following equation: Penh ϭ (Tp/Tr) ϫ (PEP/PIP). Penh measurements have been validated by Hamelmann et al. (29) in regard to identification of AHR in OVA-sensitized and -challenged mice, compared with OVA-challenged nonsensitized mice. The heightened increase in Penh with methacholine challenge in OVA-sensitized/-challenged mice was accompanied by parallel enhancement in lung airway resistance (R L ) responses to methacholine, with a high degree of correlation between Penh and R L . Moreover, these investigators found no effect of breathing pattern or respiratory rate on Penh. The pressure-time curve areas used to calculate Tr and Tp by these investigators were 64% and 36%, respectively, which are nearly identical with 65% and 35% used in the present experiments.
AHR was evaluated within 24 h of the last day of aerosol challenge (day 29). Mice were placed in separate plethysmographic chambers and allowed to acclimatize for at least 15 min before analysis. Control measurements were obtained over a 5-min control period. Afterward, increasing concentrations of methacholine in saline of 6.2, 12.5, 25, and 50 mg/ml were nebulized into the chambers for 3 min. At the end of each 3-min methacholine aerosolization, Penh measurements were taken for two consecutive 5-min periods. This was followed by challenge with the next dose of methacholine. In the analysis of Penh responses, it was found that there were no differences in Penh measurements in the first 5-min period after each methacholine challenge. However, statistically significant differences were encountered in Penh in the second 5-min period after methacholine. Therefore, the data represent measurements obtained in the second 5-min period after each methacholine challenge.
BAL (right lung) and lung fix-inflation (left lung)
After deep anesthesia with ketamine/xylazine, a 22-gauge Teflon catheter was inserted into the proximal trachea and secured with 5-0 silk suture, and the animal was ventilated (Model 687; Harvard Apparatus, South Natick, MA) at a rate of 100 and an inflation pressure of 16 cm H 2 O. Through a midline celiotomy, animals were euthanized by exsanguination through withdrawal of blood from the inferior vena cava. The blood was placed in tubes containing ethylenediamine tetraacetate for total and differential leukocyte counts and measurement of Ig levels and MCP-1.
A median sternotomy incision was performed and the left hilum was cross-clamped, as evidenced by cessation of left lung inflation by the ventilator. The right lung was lavaged through the tracheal cannula with 10 ml of 0.9% NaCl warmed to 37°C. The left hilar cross-clamp was removed, and both lungs were fix-inflated with 10% neutral buffered formalin or 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer to an inflation pressure of 25 cm H 2 O.
Identification and quantitation of leukocytes
Total leukocyte counts in peripheral blood and BAL fluid were measured with a hemacytometer. The percentages of leukocyte subsets were determined by microscopic examination of blood smears and cytocentrifuged BAL leukocytes stained in Diff-Quik (Dade Diagnostics, Aguada, Puerto Rico).
Lung histology
After fixation, lung tissue was embedded in paraffin, and sections were mounted onto glass slides by the Research Histology Core Laboratory of the Center for Research in Reproduction at the University of Virginia. Deparaffinized sections of lung tissue were stained with hematoxylin and eosin for quantitation of inflammatory infiltrates and with periodic acid/ Schiff (PAS) for quantitation of bronchial mucous gland hypertrophy. Videomicroscopic images of lung sections were analyzed with ImagePro software (Media Cybernetics, Silver Spring, MD) calibrated with a micrometer slide. In PAS-stained lung sections used for bronchial mucous gland hyperplasia, the mucosal circumference of an axial section of a bronchus was measured, which allowed conversion of total mucosal PAS-positive cells to the number of PAS-positive cells per 100 m of mucosal perimeter. The area of inflammatory cuffing around pulmonary arterioles and bronchioles also was measured by using ImagePro software.
Ag stimulation of T cells
Mice were given a single footpad and s.c. injection of OVA/alum in concentrations identical with the sensitization dose used in the airway hyperreactivity studies. Twelve days later, the mice were euthanized and regional draining lymph nodes and spleen were harvested. Tissues from two mice of each genotype were combined. The lymph node cells were dispersed in RPMI 1640 containing 100 U/ml of collagenase D (Boehringer Mannheim, Indianapolis, IN). The spleen was injected with RPMI 1640 containing collagenase D, 400 U/ml, and teased apart for dispersion of splenic cells. Cells from the lymph nodes and spleen were filtered through 100-m cell strainers (Falcon; Becton Dickinson, Franklin Lakes, NJ) into separate tubes, and lymphocytes were separated by density centrifugation with sodium diatrizoate/polysucrose (1.083 g/ml; Sigma). Mononuclear cells (interface) were aspirated and resuspended in RPMI 1640 containing penicillin/streptomycin and 50 M 2-ME. After irradiation (3000 rad) of the splenic mononuclear cells, lymphocytes (0.5 ϫ 10 6 cells/well) and spleen cells containing APCs (2 ϫ 10 6 cells/well) were cocultured in individual wells of a 24-well culture plate in the presence of increasing concentrations of OVA (0, 10, 50, or 250 g/ml). All cell isolation procedures were conducted at 4°C. The plates were placed in a 37°C incubator for 72 h in 5% CO 2 , and the supernatant from each well was aspirated and frozen at Ϫ70°C until assays for IL-4, IL-5, and IFN-␥ were performed by ELISA, as described previously (28) . Cytokine production is expressed as the fold increase in cytokine production (OD) from unstimulated cells (RPMI 1640) to cells incubated with maximum Ag (OVA, 250 g/ml), and in ng/ml determined from a standard curve.
Measurement of serum Igs
Serum Igs were measured by ELISA, as described previously (28) . Microtiter wells were coated with OVA, and diluted serum samples and standards were placed in each well. The plates were incubated at room temperature for 2 h and then washed with PBS. HRP-labeled Ab to mouse IgG1 or IgG2a, alkaline phosphatase-labeled anti-IgG2b, or biotinylated Ab to mouse IgE were added to individual wells and the plates were incubated for 2 h at room temperature. To measure IgE, avidin-labeled HRP was added to the appropriate wells after washing unbound Ab. After washing, each well was incubated with appropriate substrate and read in an automated microtiter plate at either 490 or 405 nm. The difference between the OD of the positive Ig standard and the negative control was arbitrarily assumed to represent 1000 U. The ODs of the unknown samples then were converted to units per sample by dividing the difference of the unknown OD and background by the difference between the positive control and background and multiplying the quotient by 1000.
CCR2
Ϫ/Ϫ characterization Tail DNA was isolated from nine of the CCR2 Ϫ/Ϫ mutants and six of the wt CCR2 ϩ/ϩ mice for genotypic confirmation by PCR. Two PCR primers for murine CCR2 (Ref. 30 ; GenBank U47035) were synthesized for sense position 55 (5Ј-AATATGTTACCTCAGTTCATCCAC) and antisense position 249 (5Ј-ACCAAAGATGAATACCAGGGA), which flank the BamHI insertion site of the 1.8-kb pgk-neocassette that disrupted the CCR2 gene (27) . A third probe was synthesized to the 529 sense position of neomycin (GenBank AF080389). Preliminary experiments revealed that two separate PCRs were necessary to genotype the animals. PCR with the two CCR2 primers yielded the expected DNA product of ϳ200 bp, confirming the intact CCR2 gene in the CCR2 ϩ/ϩ mice. PCR of DNA with the CCR2 sense probe and the neomycin sense probe yielded a DNA product of around 1000 bp, identifying the presence of the neomycin gene and, hence, the CCR2 Ϫ/Ϫ mutant. Assessment of mononuclear phagocyte chemotaxis to MCP-1 also was done to assess the disruption of CCR2. Peritoneal exudative cells were elicited in wt and CCR2
Ϫ/Ϫ mutant mice by peritoneal lavage of ketamine/ xylazine anesthetized animals at 72 h after i.p. injection of 2.5 ml of 0.2% sodium caseinate (31) . The harvested peritoneal exudative leukocytes were washed, quantified, and resuspended in RPMI 1640 containing 1 mg/ml BSA (fraction V; Sigma) at a concentration of 2 ϫ 10 6 cells/ml. Leukocyte chemotaxis was measured as described (32) through an acellular Poretics 5-m non-PVP polycarbonate membrane (Osmonics, Livermore, CA) with a 48-well chemotaxis chamber (Neuro Probe, Gaithersburg, MD). In duplicate, medium alone (RPMI 1640/BSA) or with recombinant murine MCP-1 (R&D Systems, Minneapolis, MN) were loaded into the lower chambers, and the upper wells then were filled with 50 l of RPMI 1640 containing 2 ϫ 10 6 of unseparated leukocytes/ml. After incubation in 5% CO 2 at 37°C for 90 min, the membrane was scraped to remove nonmigratory leukocytes. The cells were fixed in methanol, stained with Diff-Quik, and the mononuclear cells were counted within the width of a high power field (total magnification ϫ1000) across the horizontal diameter of the well. In peritoneal leukocytes from CCR2 ϩ/ϩ mice, a dose-dependent response in macrophage chemotaxis was observed in response to mMCP-1 (0.1, 1, 10, and 100 nM; data not shown). In contrast, very little chemotaxis occurred to MCP-1 by elicited peritoneal leukocytes from CCR2 Ϫ/Ϫ mice, supporting evidence for the CCR2 Ϫ/Ϫ null mutation.
ELISA for MCP-1
Plasma MCP-1 levels were measured from blood collected from each mouse at the time of euthanasia in tubes containing potassium ethylenediamine tetraacetate with a commercially available ELISA for murine MCP-1 (R&D Systems).
RNase protection assay
Lungs were removed from OVA-or saline-challenged CCR2 ϩ/ϩ and CCR2 Ϫ/Ϫ mice sacrificed under anesthesia, and total RNA extraction was performed according to the method of Chomczynski and Sacchi (33) . Total RNA was further purified by using RNeasy minispin columns (Qiagen, Valencia, CA). RNase protection assay was performed with a commercially available assay (BD PharMingen, San Diego, CA) according to the manufacturer's instructions. Riboprobes labeled with 32 P were synthesized by in vitro transcription. For each protocol, 10 g of whole lung mRNA pooled from two mice (5 g per mouse) was incubated at 56°C for 16 -20 h with the labeled riboprobe template set. Unbound riboprobes not hybridizing to mRNA were removed by adding RNase followed by phenol/chloroform-isoamyl alcohol extraction. Protected riboprobes binding to lung RNA then were electrophoresed over an acrylamide/bis-acrylamide gel (19:1). After gel transfer to filter paper, each gel was dried and placed against Kodak X-OMAT AR film in cassettes at Ϫ80°C for development of autoradiographs.
Statistical analysis of data
All data were analyzed by the SAS general linear models procedure (SAS Institute, Cary, NC; Ref. 34 ). This procedure is similar to ANOVA but is preferred when there are unequal numbers of observations between treatment groups. When an overall treatment effect was identified at the p Ͻ 0.05 level, specific differences between treatment groups were determined by Duncan's multiple range test (35) . For each variable, factorial analysis of the general linear models procedure was used to analyze for effects of genotype (CCR2 ϩ/ϩ vs CCR2
), treatment (OVA vs saline), and interaction between genotype and treatment in the mixed-background CCR2 ϩ/ϩ and CCR2
Ϫ/Ϫ mice. The factorial analysis procedure also was used in all CCR2 ϩ/ϩ groups to evaluate for effect of genetic background (mixed background, inbred C57BL/6, inbred 129/Sv), either alone or through interaction with treatment (OVA). In the text and figures, data are expressed as the mean Ϯ SEM.
Results
Respiratory responses to methacholine
In the CCR2 ϩ/ϩ and CCR2 Ϫ/Ϫ mice in the mixed-background, control Penh levels were comparable among all groups (not shown). As depicted in Fig. 1 , ⌬Penh (Penh after methacholine dose Ϫ Penh control) rose significantly ( p Ͻ 0.05) with increasing methacholine doses in both genotypes, regardless of whether challenged with OVA or saline. At the highest methacholine dose (50 mg/ml), increased airway hyperreactivity was observed in the OVA-challenged CCR2 Ϫ/Ϫ mutants, with ⌬Penh significantly higher ( p Ͻ 0.05) in the OVA-challenged CCR2 Ϫ/Ϫ mutants than ⌬Penh observed in OVA-challenged CCR2 ϩ/ϩ mice. All methacholine Penh responses for the four protocols depicted in Fig. 1 were analyzed for the effects of methacholine dose, OVA-treatment, and CCR2 status. A highly significant effect ( p Ͻ 0.05) of methacholine dose effect was present. Although there were not significant effects of CCR2 or OVA treatment alone, there was interaction ( p Ͻ 0.05) between methacholine dose, OVA-challenge, and genotype (CCR2 ϩ/ϩ vs CCR2 Ϫ/Ϫ ). There were no differences in ⌬Penh between OVA-and salinechallenged CCR2 ϩ/ϩ mice in C57BL/6 and 129/Sv backgrounds (data not shown). Fig. 2 depicts the ⌬Penh responses to the highest methacholine dose in all groups studied. Multivariate analysis of the ⌬Penh responses to methacholine for the CCR2 ϩ/ϩ mice in mixed and inbred backgrounds identified a significant methacholine dose effect ( p Ͻ 0.05), and there was significant interaction ( p Ͻ 0.05) between methacholine dose and genetic background. However, there was neither interaction between genetic background (mixed, C57BL/6, or 129/Sv) and OVA challenge, or significant interaction between methacholine dose, genetic background, and OVA challenge on AHR responses. This suggests that the enhanced AHR in the OVA-challenged CCR2 Ϫ/Ϫ mutants is unrelated to genetic background effects.
BAL eosinophilia and lung inflammation
In the mixed background, an increase in total leukocytes and percentage of eosinophils and a striking increase in absolute numbers of eosinophils were observed in the OVA-challenged CCR2
ϩ/ϩ inbred mice, although absolute BAL leukocytes did not increase in either genotype, OVA challenge led to an increase in both the percentage of eosinophils and total number of eosinophils in 129/Sv mice. Factorial analysis across the three genotypes of CCR2 ϩ/ϩ mice (mixed background and inbred C57BL/6 and 129/Sv strains) revealed significant ( p Ͻ 0.05) OVA and genetic background effects on the percentage of eosinophils in BAL, with evidence for interaction ( p Ͻ 0.05) between these effects. These observations suggest that increase in percentage of eosinophils in BAL leukocytes in the CCR2 mutants may be influenced by genetic background. However, in regard to absolute numbers of BAL eosinophils, although there was evidence of an OVA effect in the CCR2 ϩ/ϩ mice, ( p Ͻ 0.05), there was no evidence of genetic background effect or any interaction between OVA and genetic background. Thus, enhancement in BAL eosinophilia in OVA-challenged CCR2 Ϫ/Ϫ mutants is unrelated to genetic background of the mutants.
Striking histological changes in the lungs were found in OVAchallenged CCR2 Ϫ/Ϫ mice (Fig. 5B) , including profound cellular infiltrates that cuffed small bronchioles and pulmonary arterioles. Lung histological changes in OVA-challenged CCR2 ϩ/ϩ mice were barely detectable (Fig. 5A) , with evidence of slight accumulation of inflammatory cells around the small pulmonary arterioles. There was absence of histological changes in the saline-challenged mice of either genotype in the mixed background (not shown).
The area of peribronchiolar inflammatory infiltrate was significantly increased ( p Ͻ 0.05) in OVA-challenged CCR2 Ϫ/Ϫ mutants compared with OVA-challenged CCR2 ϩ/ϩ mice in mixed background (Fig. 6, left) . The increase in peribronchiolar inflammatory cuffing in the OVA-treated mutants was not related to the size of bronchioles used for morphometry, as the diameters of bronchioles were comparable at 279 Ϯ 25 and 244 Ϯ 19 m, respectively. Factorial analysis revealed significant ( p Ͻ 0.05) effects of OVA treatment and CCR2 in peribronchial cuffing. Moreover, there was interaction ( p Ͻ 0.05) between OVA and CCR2 effects. Although a small degree of peribronchiolar cuffing was observed in the inbred CCR2 ϩ/ϩ strains challenged with OVA, the changes were not significantly different from inbred controls challenged with saline (Fig. 6, right) . Factorial analysis of all CCR2 ϩ/ϩ mice revealed a significant OVA-treatment effect ( p Ͻ 0.05), but no genetic background effect was evident on peribronchial inflammatory cuffing. Thus, enhanced peribronchial cuffing of inflammatory cells in the OVA-challenged CCR2 Ϫ/Ϫ mutant is likely related to the CCR2 deletion rather than genetic background effects.
The area of the inflammatory cuffing around small pulmonary arterioles also was significantly greater ( p Ͻ 0.05) in OVA-challenged CCR2 Ϫ/Ϫ mutants, compared with OVA-challenged CCR2 ϩ/ϩ mice (Fig. 7, left) . Increased perivascular inflammatory infiltrates in the OVA-challenged mutants was not related to the size of arterioles studied, with comparable pulmonary arteriolar diameters of 87 Ϯ 9 and 71 Ϯ 8 m, respectively. In the mixed background, there was evidence on factorial analysis of significant ( p Ͻ 0.05) OVA and CCR2 effects on vascular cuffing. Moreover, there was interaction ( p Ͻ 0.05) between OVA and CCR2 effects. Although OVA challenge did not lead to an increase in perivascular cuffing in CCR2 ϩ/ϩ C57BL/6 inbred mice, OVA treatment was associated with an increase in perivascular infiltrates in CCR2 ϩ/ϩ 129/Sv mice compared with respective saline-treated control group (Fig. 7, right) . Factorial analysis of all CCR2 ϩ/ϩ groups, although not revealing a background effect, identified a significant ( p Ͻ 0.05) OVA effect, with significant interaction ( p Ͻ 0.05) between OVA and genetic background. These observations suggest that inflammatory cuffing around pulmonary arterioles in the CCR2 Ϫ/Ϫ mice may be related to differences in genetic background between the mixed-background CCR2 ϩ/ϩ and CCR2 Ϫ/Ϫ mice. PAS staining of bronchial mucosa revealed increased Goblet cell hyperplasia in OVA-challenged CCR2 Ϫ/Ϫ mice (Figs. 8 and 9) compared with OVA-challenged CCR2 ϩ/ϩ mice. In the mixed background, there were increased ( p Ͻ 0.05) numbers of PASpositive mucous-producing cells in the bronchial mucosa of OVAchallenged mutants compared with OVA-challenged CCR2 ϩ/ϩ mice (Fig. 9, left) . Factorial analysis revealed significant effects of both OVA ( p Ͻ 0.05) and CCR2 status ( p Ͻ 0.05) on the number of PAS-positive cells, and there was evidence of interaction ( p Ͻ 0.05) between these effects. There also was an increase in Goblet cell hyperplasia with OVA challenge in both C57BL/6 and 129/Sv CCR2 ϩ/ϩ inbred mice (Fig. 9 , right) compared with respective Ϫ/Ϫ mice of mixed background (left), and CCR2 ϩ/ϩ mice in 129/Sv background (right). The area of inflammatory cuffing around the pulmonary arterioles was measured as described in Fig. 6 .
saline-challenged controls. Factorial analysis of all CCR2
ϩ/ϩ mice revealed significant effects for OVA and genetic background in the number of Goblet cells, with interaction between the two effects. This suggests that enhancement in Goblet cell hyperplasia in the OVA-challenged CCR2 Ϫ/Ϫ mutants could be influenced by genetic background effects.
Serum Igs
OVA-specific serum IgG1 levels were elevated in the OVA-challenged mutants above all other groups (Fig. 10) . OVA-specific IgE also was significantly elevated in OVA-challenged CCR2 Ϫ/Ϫ mutants above all other groups (Fig. 10) . In addition, circulating IgG1 was elevated in the saline-challenged OVA-sensitized CCR2 Ϫ/Ϫ null mutants over the saline-challenged OVA-sensitized CCR2 ϩ/ϩ mice. Factorial analysis identified significant ( p Ͻ 0.05) effects of OVA treatment and CCR2 status on both circulating IgG 1 and IgE levels. However, there was no interaction identified between the two effects. IgG2a or IgG2b levels were unchanged with OVA challenge in CCR2 Ϫ/Ϫ and CCR2 ϩ/ϩ mice (data not shown).
MCP-1 levels
There was a striking 8-fold elevation ( p Ͻ 0.05) in serum MCP-1 levels (Fig. 11) in the OVA-sensitized CCR2 Ϫ/Ϫ mutants over OVA-sensitized CCR2 ϩ/ϩ mice regardless of whether the challenge was saline or OVA. OVA challenge had no effect on circulating MCP-1 levels in either genotype. Factorial analysis identified a significant ( p Ͻ 0.05) CCR2 effect but no OVA-treatment effect on serum MCP-1 levels.
Lung expression of CCR and cytokines
There was evidence for differences in lung expression of chemokine receptors in CCR2
Ϫ/Ϫ vs CCR2 ϩ/ϩ mice (Fig. 12) . This was not attributable to nonspecific up-regulation because lung expression of L32 and GADPH was comparable in all groups. In salinechallenged CCR2 Ϫ/Ϫ mutants (lane 4) there was decreased expression of CCR1, CCR3, and CCR5 compared with salinechallenged CCR2
ϩ/ϩ mice (lane 2). However, despite decreased basal expression, OVA challenge led to enhanced expression of CCR3 in CCR2
Ϫ/Ϫ mutants (lane 5), compared with comparably treated CCR2
ϩ/ϩ mice (lane 3). Moreover, there was up-regulation in CCR4 (faint band) in OVA-challenged CCR2 Ϫ/Ϫ mutants, whereas CCR4 was undetectable in all other groups. In both CCR2
Ϫ/Ϫ mutants and CCR2 ϩ/ϩ mice, OVA challenge resulted in an increase in lung expression of CCR1, CCR3, and CCR5 compared with respective saline-challenged controls for each genotype. Interestingly, although substantially less than in the CCR2 ϩ/ϩ mice, there was evidence of mild hybridization of the 32 P-labeled CCR2 riboprobe to lung RNA from the CCR2 Ϫ/Ϫ mutants (Fig. 12, lanes 3 and 4) . This is probably attributable to the fact that the 216-nt CCR2 riboprobe from BD PharMingen is complementary to a CCR2 sequence quite downstream from the BamHI neocassette insertion site at position 209. In these and subsequent experiments in which whole lung RNA is used for evaluation of expression of CCR and cytokines, increase in mRNA could occur through emigration of inflammatory cells into the lung as well as occurring through an increased expression on cells normally residing within the lung compartments.
Lung IL-13 expression increased with OVA challenge in the CCR2 Ϫ/Ϫ mutants but was undetectable in OVA-challenged CCR2 ϩ/ϩ mice or saline-challenged mice of either genotype (Fig.  13) . In addition, a faint band representing IL-5 mRNA was detected in OVA-challenged CCR2 Ϫ/Ϫ mutant, but like IL-13, IL-5 expression was undetectable in any other group. IL-4 expression was not evident in CCR2 Ϫ/Ϫ mutants or either of the CCR2 ϩ/ϩ groups. IFN-␥ expression was faintly detected in all groups, and expression appeared to be comparable in all groups.
Lymphocyte stimulation
Ag (OVA) stimulation of cells from regional lymph nodes of sensitized CCR2 Ϫ/Ϫ mice (mixed background) resulted in enhanced ( p Ͻ 0.05) IL-5 production compared with lymph node cells from CCR2 ϩ/ϩ mice (Fig. 14) . However, there were no differences in IL-4 or IFN-␥ production.
Discussion
These experiments evaluated the role of CCR2, the putative receptor for MCP-1, in a murine model of allergic airway disease. In view of previous studies that reported that neutralizing Ab to MCP-1 inhibited AHR in murine models of allergic asthma (22) (23) (24) , we expected to observe attenuation in airway inflammation and reactivity in mutant mice deficient in CCR2. Surprisingly, airway responsiveness to methacholine, as measured by the change in Penh, was significantly greater in the OVA-challenged CCR2 mutants compared with comparably challenged CCR2 ϩ/ϩ control mice. Moreover, these changes in AHR in OVA-challenged CCR2 mutants were paralleled by intense inflammatory changes that dramatically exceeded changes in CCR2 ϩ/ϩ mice. CCR2 mutants FIGURE 11. Serum MCP-1 levels were significantly elevated in CCR2 Ϫ/Ϫ mutants above CCR2 ϩ/ϩ mice (mixed background). OVA challenge did not lead to any further increase in circulating MCP-1 in either genotype. ‫,ء‬ Significantly different from wt mice challenged identically, p Ͻ 0.05.
FIGURE 12.
RNase protection assay for detection of whole-lung mRNA expression of CCR showed up-regulation in CCR3 and CCR4 in OVA-challenged CCR2 Ϫ/Ϫ mutants. Mixed-background CCR2 ϩ/ϩ mice (lanes 2 and 3) and CCR2
Ϫ/Ϫ mutant mice (lanes 4 and 5) were challenged with either saline (lanes 2 and 4) or OVA (lanes 3 and 5) . Labeled riboprobes are displayed in lane 1 as size markers and run slower than riboprobes used for RNA hybridization (lanes 2-5) because of removal of a 29-nt plasmid flanking sequences by RNase. There was equal RNA expression of the genes used to assess for nonspecific expression, L32, and GADPH. This experiment was performed twice with similar results. Ϫ/Ϫ mutants. The identification of lanes is outlined in Fig. 12 . There was equal RNA expression of the L32 and GADPH. This experiment was performed two times with similar results. treated with aerosolized OVA had profound BAL eosinophilia, Goblet cell hyperplasia, and inflammatory cuffing around the pulmonary arterioles and bronchioles. Although studies in inbred CCR2 ϩ/ϩ C57BL/6 and 129/Sv mice suggested that perivascular cuffing and Goblet cell hyperplasia in the CCR2 Ϫ/Ϫ mutants might be influenced by the relative components of the two strains in the mixed background, we found no evidence to suggest that enhanced AHR, BAL eosinophilia, and peribronchial inflammatory cuffing in the CCR2 Ϫ/Ϫ mutant were influenced by genetic background. The OVA-challenged CCR2 Ϫ/Ϫ mutants were found to have elevated serum levels of OVA-specific IgE and IgG1. The CCR2 mutants, irrespective of whether challenged with aerosolized OVA or saline, had substantial elevation of serum MCP-1 levels over circulating levels in the CCR2 ϩ/ϩ control mice. Lung expression of IL-13 was dramatically enhanced in the OVA-challenged CCR2 Ϫ/Ϫ mutants, whereas IL-13 was not detected in OVA-challenged CCR2 ϩ/ϩ mice. Lastly, Ag stimulation of lymphocytes from OVA-sensitized CCR2 mutant mice resulted in dramatic enhancement of IL-5 release, which was strikingly different from OVA-sensitized CCR2 ϩ/ϩ mice. The results in these experiments differ from a recent report that CCR2-deficient mice had attenuated rather than enhanced airway reactivity with Ag sensitization and challenge with cockroach Ag (24) , but agree with a recent report of enhanced AHR, increased lung expression of IL-5 and IL-13, and increased serum IgE in CCR2
Ϫ/Ϫ mutants challenged with intratracheal Asperigillus conidia compared with comparably challenged wt (CCR2 ϩ/ϩ ) mice (36) . In regard to the study (24) reporting attenuation of responses to cockroach Ag challenge in CCR2 Ϫ/Ϫ mutants, the study and our experiments had many differences in methods, including Ag, adjuvant, route and schedule of Ag administration, and measurement of AHR. No histological data was presented in the cockroach-challenged mutants. Therefore, reasons for differences between the studies are not clear. These experiments also differ from observations of diminished Th2-mediated lung granuloma formation in CCR2 Ϫ/Ϫ mice induced by Schistosoma egg Ag (37). However, it appears likely that diminished granuloma size was related to diminished migration of macrophages to the site of the Ag, a phenomenon observed by ourselves and others with diminished migration of macrophages to the peritoneal cavity after i.p. casein or thioglycollate administration (27, 32, 38) .
Possible explanations for enhanced AHR and lung inflammation in the Ag-sensitized CCR2 mutants in the present study include changes in lymphocyte or macrophage migration to the lung, enhanced release of histamine, and enhanced polarization of CD4 ϩ lymphocytes to a Th2 phenotype, with increased release of Th2 cytokines. Although MCP-1 may increase histamine release by mast cells and basophils (17, 18) , it is unlikely that enhanced histamine alone can lead to the lung and airway inflammation observed in the CCR2 Ϫ/Ϫ mutants. As mentioned above, CCR2
Ϫ/Ϫ mutants have diminished macrophage migration to sites of inflammatory stimulation, and it is possible that diminished migration of macrophages to the lungs of CCR2 mutants may have led to enhanced airway inflammation and responsiveness in the OVA-sensitized mutants. CCR2 Ϫ/Ϫ mutants also have deficient migration of Langerhans cells, dendritic cells in the skin, to regional lymph nodes (39) . This suggests that dendritic cell migration to the lungs or regional lymph nodes may also be impaired in CCR2
Ϫ/Ϫ mutants. Moreover, CCR2
Ϫ/Ϫ mutant mice are deficient in CD8␣ subset of dendritic cells in the spleen (39) . Because these cells stimulate Th1 differentiation of T cells, a deficiency of this subset of dendritic cells in the lungs or regional lymph nodes might result in diminished Th1 activity, with decrease in IFN-␥ production. Reduction in IFN-␥ production could enhance Th2 activity, because previous investigators have observed that IFN-␥, a Th1 cytokine, may attenuate Th2 responses (40, 41) . It also is possible that differences in T cell localization to the lungs were responsible for enhanced airway responsiveness. Although Th1 and Th2 cells both express CCR2, CCR2 is more abundantly expressed on Th1 cells, whereas CCR4 and CCR3 are prevalent on Th2 cells (42) . These data suggest that in regard to T cell localization to the lung, Th1 localization would be more impaired in CCR2 Ϫ/Ϫ mice than Th2 localization. However, insufficient localization of Th1 cells is a plausible explanation for enhanced reactivity in the CCR2 Ϫ/Ϫ mutants, in view of the above-mentioned IFN-␥ suppression of Th2 responses (40, 41) . In support of the notion that IFN-␥ activity may influence Th2 activity, chemokine profiles of children with atopic asthma reveal correlation of disease with low IFN-␥ activity (43) . These observations raise the question of whether enhanced airway responses and inflammation in the CCR2 mutants is directly related to factors that induce Th2 polarization or indirectly related to diminished Th1 activity with reduced levels of IFN-␥. Assessment of whole-lung cytokine expression reveals greater differences in expression of Th2 cytokines (IL-5, IL-13) than in IFN-␥ expression. However, reliance on whole-lung expression can be misleading, because localized attenuation in expression of IFN-␥ may still have contributed to enhancement in Th2 activity. Future studies in which localized IFN-␥ expression is assessed are required to assess this possibility. Irrespective of the mechanism, there is mounting evidence of enhanced Th2 cytokine activity in CCR2 mutants. We observed enhanced release of IL-5 and absence of IFN-␥ production after Ag stimulation of lymphocytes from regional lymph nodes of sensitized CCR2 Ϫ/Ϫ mice and up-regulation in lung expression of IL-5 and IL-13 in OVA-challenged CCR2 mutants. If the exaggerated airway responses in the OVAchallenged CCR2 mutant are related to increase in Th2 activity, it is unclear why the up-regulation in Th2 cytokines includes IL-5 and IL-13 but not IL-4. This up-regulated cytokine array is not unique and has been reported recently in Asperigillus-challenged CCR2 Ϫ/Ϫ mutants, with increase in lung IL-5 and IL-13 compared with wt mice, whereas changes in IL-4 between CCR2 Ϫ/Ϫ and wt mice were comparable (36) . Despite absence of IL-4 up-regulation in these two experiments, compared with intact mice, there was enhancement in AHR and lung inflammation, possibly attributable to the actions of IL-5 and of IL-13, which jointly share the IL-4 receptor. IL-13 itself is a potent mediator of allergic airway responses (44), possibly through stimulation of production of monocyte-derived chemokine (45, 46) . This Th2 cytokine profile evident in Asperigillus-or OVA-challenged CCR2 mutants appears to be stimulus specific, as other investigators have reported that Cryptococcus neoformans (25) and Leishmania major (39) increase IL-4 production in CCR2
Ϫ/Ϫ cells. Lastly, there is indirect evidence of IL-4 activity in the OVA-challenged CCR2 Ϫ/Ϫ mutants, with Ig subclass switching.
The 8-fold increase in circulating MCP-1 in CCR2 Ϫ/Ϫ mice compared with wt mice has been suggested previously in lung homogenates or BAL of mice challenged with A. conidia (36) or C. neoformans (25) . However, in these previous studies, discordance in MCP-1 levels between the CCR2 Ϫ/Ϫ mutant and wt mice did not occur until after infection with Cryptococcus or sensitization to Asperigillus.
In view of the increase in circulating MCP-1 in the CCR2 Ϫ/Ϫ mutants, the question could be raised as to its involvement in AHR and inflammation. Certainly, MCP-1 immunoneutralization results in attenuation of allergic AHR (22) (23) (24) , and MCP-1-deficient mice have impaired Th2 responses (20) . However, because CCR2 is the putative receptor for MCP-1 on hematopoietic cells (30, 47) , these observations seem to be at odds with observations of enhanced Th2 responses in CCR2 Ϫ/Ϫ mutants. The answer may possibly be related to elevation of circulating MCP-1 in the CCR2 Ϫ/Ϫ mutants by the hypothesis that MCP-1 mediates AHR and lung inflammation through a non-CCR2 mechanism. Evidence is conflicting about MCP-1 agonist activity for other CCR on leukocytes besides CCR2. MCP-1 induces chemotaxis of mouse lymphoma cells transfected with CCR3 (48) and stimulates calcium flux in CCR4 mRNA-injected Xenopus oocytes (49) . However, mice deficient in CCR4 have allergic airway responses that are comparable to intact mice, making CCR4 less likely as a mediator of heightened airway responses in the present study (50) . There is growing evidence that MCP-1 is able to stimulate nonhemapoietic cells through other chemokine receptors, such as MCP-1-induced expression of tissue factor by smooth muscle cells that are devoid of CCR2 (51) . Recently, an alternate receptor for MCP-1, CCR11, has been characterized in lung, liver, and intestine, but this receptor is not expressed on hematopoietic cells, and its relationship to the present observations remains unclear (52) . For the MCP-1 mediation through a non-CCR2 hypothesis to be plausible, the issue of comparable elevation of plasma MCP-1 in saline-challenged as well as OVA-challenged mutants must be resolved. If MCP-1 is a mediator of exaggerated responses, why are responses not also exaggerated in sensitized saline-challenged mice as well? One potential answer can be found in observations by Karpus Although we observed enhanced airway hyperreactivity in OVA-challenged CCR2 Ϫ/Ϫ mutants over saline-challenged mice of the same genotype, we did not see augmentation in AHR in OVA-challenged CCR2 ϩ/ϩ mice in mixed-background, inbred C57BL/6 or 129/Sv strains, compared with their respective salinechallenged controls. This may in part have been related to the C57BL/6 background, because it has been observed previously that OVA treatment augmented methacholine-induced AHR compared with saline-treated mice in BALB/c, but not in C57BL/6 or B6D2F1 mice (54) . It is unclear why OVA challenge did not enhance AHR in 129/Sv.
In summary, our findings confirm enhanced Th2 responses in mice deficient in CCR2. Moreover, this study is the first to report enhanced airway responses to methacholine, airway eosinophilia, and peribronchial and perivascular cuffing in CCR2 mutants compared with wt mice. Ag stimulation of isolated lymphocytes identified an increased production of IL-5 in OVA-sensitized CCR2 Ϫ/Ϫ mutants, which differed from responses in OVA-sensitized CCR2 ϩ/ϩ controls. Circulating MCP-1 levels were elevated 8-fold in OVA-sensitized CCR2 mutants above OVA-sensitized wt mice, regardless of whether they were challenged with OVA or saline. These studies suggest that CCR2 has an immunomodulatory role in Th2 polarization, but further studies are necessary to determine mechanisms responsible for enhancement in allergic airway responses.
